Evidence map›Paper›PMID 39027514›Full record

ArticleHeliyon2024

RHBDF1 modulates cisplatin sensitivity of small cell lung cancer through YAP1/Smad2 signaling pathway.

Lei Wang, Lishuang Qi, Xiaoyi Huang, Xiao Feng, Junqing Gan, Juxuan Zhang, Yuhui Xi, Shuai Zhang, Qingwei Meng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lei WangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Lishuang QiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, 150081, China.
Xiaoyi HuangBiotherapy Center, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Xiao FengDepartment of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong, 250013, China.
Junqing GanDepartment of Radiation Oncology, North China University of Science and Technology Affiliated Hospital, Tangshan, 063000, China.
Juxuan ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, Heilongjiang, 150081, China.
Yuhui XiDepartment of Pathophysiology, Harbin Medical University, Harbin, Heilongjiang, 150081, China.
Shuai ZhangDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.
Qingwei MengDepartment of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, 150081, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Small cell lung cancer (SCLC) is a fatal tumor type that is prone to drug resistance. In our previous study, we showed that human rhomboid-5 homolog-1 (RHBDF1) was differentially expressed in 5 intrinsic cisplatin-resistant SCLC tissues compared with 5 intrinsic cisplatin-sensitive SCLC tissues by RNA sequencing, which intrigued us. We performed gain- and loss-of-function experiments to investigate RHBDF1 function, bioinformatics analysis, qRT-PCR, western blotting, and immunoprecipitation to elucidate the molecular mechanisms as well as detect RHBDF1 expression in SCLC by immunohistochemistry. We found that RHBDF1 knockdown promoted cell proliferation and cisplatin chemoresistance and inhibited apoptosis in

Indexed as

ChemoresistanceRHBDF1SCLCYAP1/Smad2 signaling

Identifiers

PMID39027514
PMCPMC11254170

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.